Detalles de la búsqueda
1.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36632738
2.
The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Br J Haematol
; 193(3): 542-550, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33792026
3.
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica
; 106(4): 1079-1085, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32107329
4.
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.
Haematologica
; 105(1): 193-200, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31221778
5.
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies.
Haematologica
; 104(8): 1640-1647, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30733270
6.
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica
; 103(7): 1209-1217, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29674504
7.
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
Am J Hematol
; 92(6): 529-535, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28295527
8.
Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
Br J Haematol
; 170(4): 523-31, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26010293
9.
Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters.
Blood
; 119(10): 2310-3, 2012 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-22246039
10.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
Blood Cancer J
; 14(1): 94, 2024 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38849344
11.
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Transplant Cell Ther
; 30(6): 580.e1-580.e14, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582286
12.
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Cancers (Basel)
; 16(6)2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539561
13.
Array CGH analysis reveals deletion of chromosome 22q11 in CLL with normal karyotype and no fish alterations.
Br J Haematol
; 183(1): 152-155, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28990183
14.
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Blood
; 118(12): 3419-25, 2011 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-21816830
15.
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation.
Ann Hematol
; 92(9): 1271-80, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23660628
16.
6q deletion detected by fluorescence in situ hybridization using bacterial artificial chromosome in chronic lymphocytic leukemia.
Eur J Haematol
; 91(1): 10-9, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23560441
17.
Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia-a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant
; 58(8): 907-915, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37160941
18.
Long-term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine-venetoclax.
EJHaem
; 3(2): 517-520, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35846058
19.
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
Clin Lymphoma Myeloma Leuk
; 22(3): 198-204, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34690088
20.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
J Clin Oncol
; 40(27): 3120-3131, 2022 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35666982